Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT: Pregabalin for Prevention of Persistent Pain in High Risk Patients Undergoing Breast Cancer Surgery
NCT03216187Phase 3Terminated
- Start
- Jan 2018
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic post-surgical pain (CPSP) comparing Pregabalin with Placebo (2 arms). Primary endpoint: Incidence of clinically important pain at 3 months. Started Jan 2018; status: terminated.
02
Drugs
pregabalin
03
Conditions
chronic post-surgical pain (CPSP)
Beyond the preview
Go deeper on NCT03216187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03216187.